Compare UUUU & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUUU | NAMS |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.1B |
| IPO Year | 2006 | N/A |
| Metric | UUUU | NAMS |
|---|---|---|
| Price | $15.13 | $31.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $19.92 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 10.0M | 1.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,922,000.00 | N/A |
| Revenue This Year | $126.63 | $17.96 |
| Revenue Next Year | $36.80 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.24 | $17.76 |
| 52 Week High | $27.90 | $42.21 |
| Indicator | UUUU | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 40.44 |
| Support Level | $13.40 | $30.34 |
| Resistance Level | $16.63 | $31.72 |
| Average True Range (ATR) | 1.25 | 1.69 |
| MACD | -0.28 | -0.56 |
| Stochastic Oscillator | 8.73 | 6.04 |
Energy Fuels Inc is a critical mineral company based in the U.S. It produces several critical minerals, including uranium, vanadium, REEs (including NdPr, Dy and Tb) and HMS (including titanium and zirconium minerals). The company's project portfolio comprises uranium properties like Pinyon Plain Project, White Mesa Mill, Roca Honda Project, etc.; Heavy Minerals Sands project like Vara Mada Project, Donald Project, Bahia Project, etc.; the Nichols Ranch Project, and several other properties. The firm's reportable segments are: Uranium, REE, and HMS. Key revenue is generated from the Uranium segment, which is involved in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties, and the recycling of uranium-bearing materials generated by third parties.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.